<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39457216</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Children (Basel, Switzerland)</Title><ISOAbbreviation>Children (Basel)</ISOAbbreviation></Journal><ArticleTitle>Down Syndrome in Children: A Primary Immunodeficiency with Immune Dysregulation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1251</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/children11101251</ELocationID><Abstract><AbstractText><b>Background:</b> The multisystemic features of Down syndrome (DS) in children are accompanied by immunodeficiency, making them susceptible to infections and immune dysregulation with autoimmune, allergic, inflammatory, and hematological complications. This study was aimed at a better understanding of the abnormalities within the B and T cell compartments and their correlations with clinical immunophenotypes. <b>Methods:</b> Medical records of 35 DS children were retrospectively reviewed, referring to clinical symptomatology including history of infections, immune dysregulation disorders, and humoral and cellular immune response. <b>Results:</b> While the etiology of respiratory tract infections included typical viral and bacterial pathogens, SARS-CoV2-induced inflammatory disease and syndromic immunodeficiency contributed significantly to the deterioration of the clinical course. Allergic diseases in the form of asthma, allergic rhinitis, and alimentary allergy were the most frequent manifestations of immune dysregulation and were followed by autoimmune disorders, such as Crohn's disease, celiac disease, autoimmune thyroiditis, and alopecia, as well as inflammatory disorders, balanitis xerotica obliterans and lymphadenopathy, and a hematological disorder of myelopoiesis. Deficiency of serum immunoglobulin levels, reduced numbers of naïve B cells, and non-switched memory B cells along with low naïve T helper cells and significantly reduced regulatory T helper cells were the most prominent immune abnormalities. <b>Conclusions:</b> The loss of naïveté in B and T lymphocyte compartments with a deficiency of regulatory T cells may be underpinning pathomechanisms for the skewed immune response. The clinical immunophenotype in DS is complex and represents syndromic primary immunodeficiency with immune dysregulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szczawińska-Popłonyk</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Pneumonology, Allergy and Clinical Immunology, Institute of Pediatrics, Poznań University of Medical Sciences, Szpitalna 27/33, 60-572 Poznań, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popłonyk</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Student Scientific Society, Poznań University of Medical Sciences, 61-701 Poznań, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awdi</LastName><ForeName>Karina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0009-4862-3614</Identifier><AffiliationInfo><Affiliation>Student Scientific Society, English Division, Poznań University of Medical Sciences, 61-701 Poznań, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Children (Basel)</MedlineTA><NlmUniqueID>101648936</NlmUniqueID><ISSNLinking>2227-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Down syndrome</Keyword><Keyword MajorTopicYN="N">allergy</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">immune dysregulation</Keyword><Keyword MajorTopicYN="N">primary immunodeficiency</Keyword><Keyword MajorTopicYN="N">regulatory T cells</Keyword></KeywordList><CoiStatement>All authors declare no existing financial and non-financial conflicts of interest regarding this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457216</ArticleId><ArticleId IdType="pmc">PMC11506678</ArticleId><ArticleId IdType="doi">10.3390/children11101251</ArticleId><ArticleId IdType="pii">children11101251</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Graaf G., Buckley F., Skotko B.G. Estimation of the number of people with Down syndrome in Europe. Eur. J. Hum. Genet. 2021;29:402–410. doi: 10.1038/s41431-020-00748-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-020-00748-y</ArticleId><ArticleId IdType="pmc">PMC7940428</ArticleId><ArticleId IdType="pubmed">33130823</ArticleId></ArticleIdList></Reference><Reference><Citation>De Graaf G., Buckley F., Skotko B.G. Estimates of live births, natural losses, and elective terminations with Down syndrome in the United States. Am. J. Med. Genet. 2015;167A:756–767. doi: 10.1002/ajmg.a.37001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.37001</ArticleId><ArticleId IdType="pubmed">25822844</ArticleId></ArticleIdList></Reference><Reference><Citation>Presson A.P., Partyka G., Jensen K.M., Devine O.J., Rasmussen S.A., McCabe L.L., McCabe E.R. Current estimates of Down syndrome population prevalence in the United States. J. Pediatr. 2013;163:1163–1168. doi: 10.1016/j.jpeds.2013.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2013.06.013</ArticleId><ArticleId IdType="pmc">PMC4445685</ArticleId><ArticleId IdType="pubmed">23885965</ArticleId></ArticleIdList></Reference><Reference><Citation>Asim A., Kumar A., Muthuswamy S., Jain S., Agarwal S. Down syndrome: An insight of the disease. J. Biomed. Sci. 2015;22:41. doi: 10.1186/s12929-015-0138-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-015-0138-y</ArticleId><ArticleId IdType="pmc">PMC4464633</ArticleId><ArticleId IdType="pubmed">26062604</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam A., Raja K., Venugopalan M., Chandrasekaran B., Sampath K.K., Muthusamy H., Shanmugam N. Down syndrome-a narrative review with a focus on anatomical features. Clin. Anat. 2016;29:568–577. doi: 10.1002/ca.22672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ca.22672</ArticleId><ArticleId IdType="pubmed">26599319</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lausnay M., Ides K., Wojciechowski M., Boudewyns A., Verhulst S., Van Hoorenbeeck K. Pulmonary complications in children with Down syndrome: A scoping review. Paediatr. Resp. Rev. 2021;40:65–72. doi: 10.1016/j.prrv.2021.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prrv.2021.04.006</ArticleId><ArticleId IdType="pubmed">34148805</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsubie H.S., Rosen D. The evaluation and management of respiratory disease in children with Down syndrome (DS) Paediatr. Resp. Rev. 2018;26:49–54. doi: 10.1016/j.prrv.2017.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prrv.2017.07.003</ArticleId><ArticleId IdType="pubmed">29033214</ArticleId></ArticleIdList></Reference><Reference><Citation>Danopoulos S., Deutsch G.H., Dumortier C., Mariani T.J., Al Alam D. Lung disease manifestations in Down syndrome. Am. J. Physiol. Lung Cell Mol. Physiol. 2021;321:892–899. doi: 10.1152/ajplung.00434.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00434.2020</ArticleId><ArticleId IdType="pmc">PMC8616621</ArticleId><ArticleId IdType="pubmed">34469245</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstegen R.H.J., Chang K.J.J., Kusters M.A.A. Clinical implications of immune-mediated diseases in children with Down syndrome. Pediatr. Allergy Immunol. 2020;31:117–123. doi: 10.1111/pai.13133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.13133</ArticleId><ArticleId IdType="pubmed">31599041</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczawinska-Poplonyk A., Begier K., Dorota A., Dabrowska M., Galecka D., Wawrzeniak K., Wroblewski K. Syndromic immunodeficiencies: A pediatrician’s perspective on selected diseases. Allergol. Immunopathol. 2021;49:117–136. doi: 10.15586/aei.v49i4.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.15586/aei.v49i4.200</ArticleId><ArticleId IdType="pubmed">34224226</ArticleId></ArticleIdList></Reference><Reference><Citation>Krivega M., Stiefel C.M., Storchova Z. Consequences of the chromosome gain: A new view on trisomy syndromes. Am. J. Hum. Genet. 2022;109:2126–2140. doi: 10.1016/j.ajhg.2022.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2022.10.014</ArticleId><ArticleId IdType="pmc">PMC9808507</ArticleId><ArticleId IdType="pubmed">36459979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chunduri N.K., Storchova Z. The diverse consequences of aneuploidy. Nat. Cell Biol. 2019;21:2010–2021. doi: 10.1038/s41556-018-0243-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0243-8</ArticleId><ArticleId IdType="pubmed">30602769</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonarakis S.E., Skotko B.G., Rafii M.S., Strydom A., Pape S.E., Bianchi D.W., Sherman S.L., Reeves R.H. Down syndrome. Nat. Rev. Dis. Primers. 2020;6:9–20. doi: 10.1038/s41572-019-0143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0143-7</ArticleId><ArticleId IdType="pmc">PMC8428796</ArticleId><ArticleId IdType="pubmed">32029743</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggard D., Doherty D.G., Molloy E.J. Immune dysregulation in children with Down syndrome. Front. Pediatr. 2020;8:73. doi: 10.3389/fped.2020.00073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2020.00073</ArticleId><ArticleId IdType="pmc">PMC7056667</ArticleId><ArticleId IdType="pubmed">32175298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramba M., Bogunovic D. The immune system in Down syndrome: Autoimmunity and severe infections. Immunol. Rev. 2024;322:300–310. doi: 10.1111/imr.13296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13296</ArticleId><ArticleId IdType="pmc">PMC10950520</ArticleId><ArticleId IdType="pubmed">38050836</ArticleId></ArticleIdList></Reference><Reference><Citation>Satgé D., Seidel M.G. The pattern of malignancies in Down syndrome and its potential context with the immune system. Front. Immunol. 2018;9:3058. doi: 10.3389/fimmu.2018.03058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03058</ArticleId><ArticleId IdType="pmc">PMC6315194</ArticleId><ArticleId IdType="pubmed">30631328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram G., Chinen J. Infections and ammunodeficiency in Down syndrome. Clin. Exp. Immunol. 2011;164:9–16. doi: 10.1111/j.1365-2249.2011.04335.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2011.04335.x</ArticleId><ArticleId IdType="pmc">PMC3074212</ArticleId><ArticleId IdType="pubmed">21352207</ArticleId></ArticleIdList></Reference><Reference><Citation>Piatosa B., Wolska-Kuśnierz B., Pac M., Siewiera K., Gałkowska E., Bernatowska E. B cell subsets in healthy children: Reference values for evaluation of B cell maturation process in peripheral blood. Cytometry B Clin. Cytom. 2010;78:372–381. doi: 10.1002/cyto.b.20536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.b.20536</ArticleId><ArticleId IdType="pubmed">20533385</ArticleId></ArticleIdList></Reference><Reference><Citation>Schatorje E.J.H., Gemen E.F.A., Driessen G.J.A., Leuvenink J., van Hout R.W.N.M., de Vries E. Paediatric reference values for the peripheral T cell compartment. Scand. J. Immunol. 2012;75:436–444. doi: 10.1111/j.1365-3083.2012.02671.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.2012.02671.x</ArticleId><ArticleId IdType="pubmed">22420532</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggard D., Worrall A.P., Kirkham C., McGrane F., Mandira R., Casey L., Condon T., George S., Lagan N., Roche E., et al. Immune screening in children with Down syndrome. Acta Paediatr. 2022;111:2025–2028. doi: 10.1111/apa.16489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.16489</ArticleId><ArticleId IdType="pmc">PMC9541023</ArticleId><ArticleId IdType="pubmed">35842744</ArticleId></ArticleIdList></Reference><Reference><Citation>Eissa E., Afifi H.H., Abo-Shanab A.M., Thomas M.M., Taher M.B., Kandil R., Kholoussi N.M. Importance of TREC and KREC as molecular markers for immunological evaluation of Down syndrome children. Sci. Rep. 2023;13:15445. doi: 10.1038/s41598-023-42370-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-42370-0</ArticleId><ArticleId IdType="pmc">PMC10507011</ArticleId><ArticleId IdType="pubmed">37723211</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstegen R.H.J., Kusters M.A.A. Inborn errors of adaptive immunity in Down syndrome. J. Clin. Immunol. 2020;40:791–806. doi: 10.1007/s10875-020-00805-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-020-00805-7</ArticleId><ArticleId IdType="pubmed">32638194</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstegen R.H., Borte S., Bok L.A., van Zwieten P.H., von Döbeln U., Hammarström L., de Vries E. Impact of Down syndrome on the performance of neonatal screening assays for severe primary immunodeficiency diseases. J. Allergy Clin. Immunol. 2014;133:1208–1211. doi: 10.1016/j.jaci.2013.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2013.10.010</ArticleId><ArticleId IdType="pubmed">24332217</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsetti R., Valentini D., Marcellini V., Scarsella M., Marasco E., Giustini F., Bartuli A., Villani A., Ugazio A.G. Reduced numbers of switched memory B cells with high terminal differentiation potential in Down syndrome. Eur. J. Immunol. 2015;45:903–914. doi: 10.1002/eji.201445049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201445049</ArticleId><ArticleId IdType="pmc">PMC4674966</ArticleId><ArticleId IdType="pubmed">25472482</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya M., Kwak K., Pierce S.K. B cell memory: Building two walls of protection against pathogens. Nat. Rev. Immunol. 2020;20:229–238. doi: 10.1038/s41577-019-0244-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0244-2</ArticleId><ArticleId IdType="pmc">PMC7223087</ArticleId><ArticleId IdType="pubmed">31836872</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstegen R.H., Driessen G.J., Bartol S.J., van Noesel C.J., Boon L., van der Burg M., van Dongen J.J., de Vries E., van Zelm M.C. Defective B cell memory in patients with Down syndrome. J. Allergy Clin. Immunol. 2014;134:1346–1353. doi: 10.1016/j.jaci.2014.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.07.015</ArticleId><ArticleId IdType="pubmed">25159464</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstegen R.H.J., Kusters M.A.A., Gemen E.F.A., de Vries E. Down syndrome B lymphocyte subpopulations, intrinsic defect or decreased T lymphocyte help. Pediatr. Res. 2010;67:563–569. doi: 10.1203/PDR.0b013e3181d4ecc1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e3181d4ecc1</ArticleId><ArticleId IdType="pubmed">20098344</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczawinska-Poplonyk A., Schwartzmann E., Bukowska-Olech E., Biernat M., Gattner S., Korobacz T., Nowicki F., Wiczuk-Wiczewska M. The pediatric common variable immunodeficiency—From genetics to therapy: A review. Eur. J. Pediatr. 2022;181:1371–1383. doi: 10.1007/s00431-021-04287-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-04287-6</ArticleId><ArticleId IdType="pmc">PMC8964589</ArticleId><ArticleId IdType="pubmed">34939152</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczawińska-Popłonyk A., Tąpolska-Jóźwiak K., Schwartzmann E., Popłonyk N. Immune dysregulation in pediatric common variable immunodeficiency. Front. Pediatr. 2022;10:855200. doi: 10.3389/fped.2022.855200.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.855200</ArticleId><ArticleId IdType="pmc">PMC8983883</ArticleId><ArticleId IdType="pubmed">35402361</ArticleId></ArticleIdList></Reference><Reference><Citation>Gensous N., Bacalini M.G., Franceschi C., Garagnani P. Down syndrome, accelerated aging and immunosenescence. Semin. Immunopathol. 2020;42:635–645. doi: 10.1007/s00281-020-00804-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-020-00804-1</ArticleId><ArticleId IdType="pmc">PMC7666319</ArticleId><ArticleId IdType="pubmed">32705346</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcovecchio G.E., Ferrua F., Fontana E., Beretta S., Genua M., Bortolomai I., Conti A., Montin D., Cascarano M.T., Bergante S., et al. Premature senescence and increased oxidative stress in the thymus of Down syndrome patients. Front. Immunol. 2021;12:669893. doi: 10.3389/fimmu.2021.669893.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.669893</ArticleId><ArticleId IdType="pmc">PMC8204718</ArticleId><ArticleId IdType="pubmed">34140950</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos J.S., Henrickson S.E. Defining and targeting patterns of T cell dysfunction in inborn errors of immunity. Front. Immunol. 2022;13:932715. doi: 10.3389/fimmu.2022.932715.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.932715</ArticleId><ArticleId IdType="pmc">PMC9516113</ArticleId><ArticleId IdType="pubmed">36189259</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeters D., Pico-Knijnenburg I., Wieringa D., Rad M., Cuperus R., Ruige M., Froeling F., Zijp G.W., van der Burg M., Driessen G.J.A. AKT hyperphosphorylation and T cell exhaustion in Down syndrome. Front. Immunol. 2022;13:724436. doi: 10.3389/fimmu.2022.724436.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.724436</ArticleId><ArticleId IdType="pmc">PMC8866941</ArticleId><ArticleId IdType="pubmed">35222360</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmonte O.M., Castagnoli R., Calzoni E., Notarangelo L.D. Inborn errors of immunity with immune dysregulation: From bench to bedside. Front. Pediatr. 2019;7:353. doi: 10.3389/fped.2019.00353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00353</ArticleId><ArticleId IdType="pmc">PMC6718615</ArticleId><ArticleId IdType="pubmed">31508401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari M., Stagi S. Autoimmunity and genetic syndromes: A focus on Down syndrome. Genes. 2021;12:268. doi: 10.3390/genes12020268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12020268</ArticleId><ArticleId IdType="pmc">PMC7918365</ArticleId><ArticleId IdType="pubmed">33668420</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggard D., Kelly L., Ryan E., McGrane F., Lagan N., Roche E., Balfe J., Leahy T.R., Franklin O., Doherty D.G., et al. Increased systemic inflammation in children with Down syndrome. Cytokine. 2020;127:154938. doi: 10.1016/j.cyto.2019.154938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2019.154938</ArticleId><ArticleId IdType="pubmed">31785499</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Che M., Yuan J., Yu Y., Cao C., Qin X.-Y., Cheng Y. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: A meta-analysis. Oncotarget. 2017;8:84489–84496. doi: 10.18632/oncotarget.21060.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.21060</ArticleId><ArticleId IdType="pmc">PMC5663613</ArticleId><ArticleId IdType="pubmed">29137441</ArticleId></ArticleIdList></Reference><Reference><Citation>Araya P., Waugh K.A., Sullivan K.D., Núñez N.G., Roselli E., Smith K.P., Granrath R.E., Rachubinski A.L., Estrada B.E., Butcher E.T., et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc. Natl. Acad. Sci. USA. 2019;116:24231–24241. doi: 10.1073/pnas.1908129116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1908129116</ArticleId><ArticleId IdType="pmc">PMC6883781</ArticleId><ArticleId IdType="pubmed">31699819</ArticleId></ArticleIdList></Reference><Reference><Citation>Aversa T., Crisafulli G., Zirilli G., De Luca F., Gallizzi R., Valenzise M., Aversa T., Crisafulli G., Zirilli G., De Luca F., et al. Epidemiological aspects of autoimmune thyroide disease in children with Down’s syndrome. Ital. J. Pediatr. 2018;44:39. doi: 10.1186/s13052-018-0478-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-018-0478-9</ArticleId><ArticleId IdType="pmc">PMC5863361</ArticleId><ArticleId IdType="pubmed">29562915</ArticleId></ArticleIdList></Reference><Reference><Citation>Guaraldi F., Giaccherino R.R., Lanfranco F., Motta G., Gori D., Arvat E., Ghigo E., Giordano R. Endocrine autoimmunity in Down’s syndrome. Front. Horm. Res. 2017;48:133–146. doi: 10.1159/000452912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000452912</ArticleId><ArticleId IdType="pubmed">28245458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hom B., Boyd N.K., Vogel B.N., Nishimori N., Khoshnood M.M., Jafarpour S., Nagesh D., Santoro J.D. Down Syndrome and Autoimmune Disease. Clin. Rev. Allergy Immunol. 2024;66:261–273. doi: 10.1007/s12016-024-08996-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-024-08996-2</ArticleId><ArticleId IdType="pmc">PMC11422465</ArticleId><ArticleId IdType="pubmed">38913142</ArticleId></ArticleIdList></Reference><Reference><Citation>Guild A., Fritch J., Patel S., Reinhardt A., Acquazzino M. Hemophagocytic lymphohistiocytosis in trisomy 21: Successful treatment with interferon inhibition. Pediatr. Rheumatol. Online J. 2022;20:104. doi: 10.1186/s12969-022-00764-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-022-00764-w</ArticleId><ArticleId IdType="pmc">PMC9673190</ArticleId><ArticleId IdType="pubmed">36401314</ArticleId></ArticleIdList></Reference><Reference><Citation>Skogberg G., Lundberg V., Lindgren S., Gudmundsdottir J., Sandström K., Kämpe O., Annerén G., Gustafsson J., Sunnegårdh J., van der Post S., et al. Altered expression of autoimmune regulator in infant down syndrome thymus, a possible contributor to autoimmune phenotype. J. Immunol. 2014;193:2187–2195. doi: 10.4049/jimmunol.1400742.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1400742</ArticleId><ArticleId IdType="pmc">PMC4135177</ArticleId><ArticleId IdType="pubmed">25038256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacalini M.G., Gentilini D., Boattini A., Giampieri E., Pirazzini C., Giuliani C., Fontanesi E., Scurti M., Remondini D., Capri M., et al. Identification of a DNA methylation signature in blood cells from persons with Down syndrome. Aging. 2015;7:82–96. doi: 10.18632/aging.100715.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100715</ArticleId><ArticleId IdType="pmc">PMC4359691</ArticleId><ArticleId IdType="pubmed">25701644</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung C., Su L., Simões-E-Silva A.C., Arocha L.S., de Paiva K.M., Haas P. Risk for severe illness and death among pediatric patients with Down syndrome hospitaliza for COVID-19, Brazil. Emerg. Infect. Dis. 2023;29:126–135. doi: 10.3201/eid2901.220530.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2901.220530</ArticleId><ArticleId IdType="pmc">PMC9796221</ArticleId><ArticleId IdType="pubmed">36573520</ArticleId></ArticleIdList></Reference><Reference><Citation>Velammal P.N.K.P., Balasubramanian S., Ayoobkhan F.S., Mohan G.V.K., Aggarwal P., Rabaan A.A., Khan S.A., Yasmin F., Koritala T., Surani S.R. COVID-19 in patients with Down syndrome: A systematic review. Immun. Inflamm. Dis. 2024;12:1219. doi: 10.1002/iid3.1219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.1219</ArticleId><ArticleId IdType="pmc">PMC10949394</ArticleId><ArticleId IdType="pubmed">38501534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kołtan S., Ziętkiewicz M., Grześk E., Becht R., Berdej-Szczot E., Cienkusz M., Ewertowska M., Heropolitańska-Pliszka E., Krysiak N., Lewandowicz-Uszyńska A., et al. COVID-19 in unvaccinated patients with inborn errors of immunity—Polish experience. Front. Immunol. 2022;13:953700. doi: 10.3389/fimmu.2022.953700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.953700</ArticleId><ArticleId IdType="pmc">PMC9537609</ArticleId><ArticleId IdType="pubmed">36211407</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa J.M. Down syndrome and COVID-19: A perfect storm? Cell Rep. Med. 2020;1:100019. doi: 10.1016/j.xcrm.2020.100019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100019</ArticleId><ArticleId IdType="pmc">PMC7252041</ArticleId><ArticleId IdType="pubmed">32501455</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczawińska-Popłonyk A., Jończyk-Potoczna K., Bręborowicz A., Bartkowska-Śniatkowska A., Figlerowicz M. Fatal respiratory distress syndrome due to coronavirus infection in a child with severe combined immunodeficiency. Influenza Other Respir. Viruses. 2013;7:634–636. doi: 10.1111/irv.12059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12059</ArticleId><ArticleId IdType="pmc">PMC5781196</ArticleId><ArticleId IdType="pubmed">23199056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogimi C., Englund J.A., Bradford M.C., Qin X., Boeckh M., Waghmare A. Characteristics and outcomes of coronavirus infection in children: The role of viral factors and an immunocompromised state. J. Pediatr. Infect. Dis. Soc. 2019;8:21–28. doi: 10.1093/jpids/pix093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/pix093</ArticleId><ArticleId IdType="pmc">PMC6437838</ArticleId><ArticleId IdType="pubmed">29447395</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick V., Rivelli A., Chaudhari S., Chicoine L., Jia G., Rzhetsky A., Chicoine B. Prevalence of infectious diseases among 6078 individuals with Down syndrome in the United States. J. Patient-Centered Res. Rev. 2022;9:64–69. doi: 10.17294/2330-0698.1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.17294/2330-0698.1876</ArticleId><ArticleId IdType="pmc">PMC8772611</ArticleId><ArticleId IdType="pubmed">35111884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezzi M., Garancini N., De Santis R., Gianolio L., Zirpoli S., Mandelli A., Farolfi A., D’auria E., Zuccotti G.V. Recurrent respiratory infections in children with Down syndrome: A review. Children. 2014;11:246. doi: 10.3390/children11020246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children11020246</ArticleId><ArticleId IdType="pmc">PMC10888118</ArticleId><ArticleId IdType="pubmed">38397357</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijsvoogel N.B., Verstegen R.H.J., van Well G.T.J., van Hout R.W.N.M., de Vries E. Increased rate of respiratory symptoms in children with Down syndrome: A 2-year web-based parent-reported prospective study. Eur. J. Pediatr. 2022;181:4079–4089. doi: 10.1007/s00431-022-04634-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-022-04634-1</ArticleId><ArticleId IdType="pmc">PMC9649482</ArticleId><ArticleId IdType="pubmed">36192547</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarangelo L.D., Bosticardo M. Interferons in Down syndrome: When more is less. Immunity. 2022;55:1967–1969. doi: 10.1016/j.immuni.2022.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.10.011</ArticleId><ArticleId IdType="pmc">PMC10593427</ArticleId><ArticleId IdType="pubmed">36351368</ArticleId></ArticleIdList></Reference><Reference><Citation>Malle L., Bogunovic D. Down syndrome and type I interferon: Not so simple. Curr. Opin. Immunol. 2022;72:196–205. doi: 10.1016/j.coi.2021.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2021.06.006</ArticleId><ArticleId IdType="pmc">PMC8578175</ArticleId><ArticleId IdType="pubmed">34174697</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R.S., Martin-Fernandez M., Stewart O.J., Philippot Q., Buta S., Richardson A., Barcessat V., Taft J., Bastard P., Samuels J., et al. Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11+ B cells. Nature. 2023;615:305–314. doi: 10.1038/s41586-023-05736-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-05736-y</ArticleId><ArticleId IdType="pmc">PMC9945839</ArticleId><ArticleId IdType="pubmed">36813963</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti M.K., Cyprian F.S., Nasrallah G.K., Al Thani A.A., Almishal R.O., Yassine H.M. Viruses and autoimmunity: A review on the potential interaction an molecular mechanisms. Viruses. 2019;11:762. doi: 10.3390/v11080762.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11080762</ArticleId><ArticleId IdType="pmc">PMC6723519</ArticleId><ArticleId IdType="pubmed">31430946</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo-Cortes A., Rodriguez-Pinto D., Aguillar-Ayala L. Evidence of molecular mimicry between SARS-CoV-2 and human antigens: Implications for autoimmunity in COVID-19. Autoimmune Dis. 2024;2024:8359683. doi: 10.1155/2024/8359683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2024/8359683</ArticleId><ArticleId IdType="pmc">PMC11380714</ArticleId><ArticleId IdType="pubmed">39247752</ArticleId></ArticleIdList></Reference><Reference><Citation>Biselli J.M., Zampieri B.L., Biselli-Chicote P.M., de Souza J.E.S., Bürger M.C., da Silva W.A., Jr., Goloni-Bertollo E.M., Pavarino C. Differential microRNA expression profile in blood of children with Down syndrome suggests a role in immunological dysfunction. Hum. Cell. 2022;35:639–648. doi: 10.1007/s13577-022-00672-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-022-00672-x</ArticleId><ArticleId IdType="pmc">PMC8773395</ArticleId><ArticleId IdType="pubmed">35060072</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruchel A., Bourquin J.-P., Crispino J., Cuartero S., Hasle H., Hitzler J., Klusmann J.-H., Izraeli S., Lane A.A., Malinge S., et al. Down syndrome and leukemia: From basic mechanisms to clinical advances. Haematologica. 2023;108:2570–2581. doi: 10.3324/haematol.2023.283225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2023.283225</ArticleId><ArticleId IdType="pmc">PMC10542835</ArticleId><ArticleId IdType="pubmed">37439336</ArticleId></ArticleIdList></Reference><Reference><Citation>Peroni E., Gottardi M., D’Antona L., Randi M.L., Rosato A., Coltro G. Hematologic neoplasms associated with Down syndrome: Cellular and molecular heterogeneity of the disease. Int. J. Mol. Sci. 2023;24:15325. doi: 10.3390/ijms242015325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242015325</ArticleId><ArticleId IdType="pmc">PMC10607483</ArticleId><ArticleId IdType="pubmed">37895004</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome. Pediatr. Int. 2019;61:222–229. doi: 10.1111/ped.13776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ped.13776</ArticleId><ArticleId IdType="pubmed">30593694</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Kalev-Zylinska M.L. Advances in molecular characterization of myeloid proliferations associated with Down syndrome. Front. Genet. 2022;13:891214. doi: 10.3389/fgene.2022.891214.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.891214</ArticleId><ArticleId IdType="pmc">PMC9399805</ArticleId><ArticleId IdType="pubmed">36035173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrix J.A., Amon A., Abbeduto L., Agiovlasitis S., Alsaied T., Anderson H.A., Bain L.J., Baumer N., Bhattacharyya A., Bogunovic D., et al. Opportunities, barriers, and recommendations in Down syndrome research. Transl. Sci. Rare Dis. 2021;5:99–129. doi: 10.3233/TRD-200090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/TRD-200090</ArticleId><ArticleId IdType="pmc">PMC8279178</ArticleId><ArticleId IdType="pubmed">34268067</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gameren-Oosterom H.B.M., Weijerman M.E., van Wieringen H., de Winter J.P., van Wermeskerken A. Clinical practice-latest insights in optimizing the care of children with Down syndrome. Eur. J. Pediatr. 2023;182:2027–2039. doi: 10.1007/s00431-023-04890-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-023-04890-9</ArticleId><ArticleId IdType="pubmed">36897403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>